Clinical trials: Pituitary-Adrenal System
Cushing's Syndrome
An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Participants in study C-1073-400 (NCT00569582) will be invited to participate in this extension study to examine the long term safety of mifepristone in the treatment of the signs and symptoms of endogenous Cushing's syndrome.
- Trial name
- NCT00936741
- Testing
- mifepristone
- Where
- 15 sites in United States
- Volunteers
- 30 people
- Sponsor
- Corcept Therapeutics
Psoriasis, Atopic Dermatitis
Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population
The purpose of this study is to determine the effect of Pandel® (hydrocortisone probutate cream) Cream 0.1% on the Hypothalamic Pituitary Adrenal (HPA) axis in pediatric and adult subjects with either psoriasis or atopic…
- Trial name
- NCT01137032
- Testing
- Pandel Cream 0.1%
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Fougera Pharmaceuticals Inc.
Cushing Syndrome
A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
This is a Phase 3, double-blind, placebo-controlled, randomized-withdrawal study to assess the efficacy, safety and pharmacokinetics (PK) of relacorilant in patients with endogenous Cushing syndrome and concurrent type 2 diabetes…
- Trial name
- GRACE (NCT03697109)
- Testing
- Relacorilant
- Where
- 64 sites in United States, Austria and 9 more
- Volunteers
- 152 people
- Sponsor
- Corcept Therapeutics
Perennial Allergic Rhinitis
Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)
The purpose of the study is to evaluate the effects of BDP HFA Nasal Aerosol on HPA-axis function.
- Trial name
- NCT01133626
- Testing
- Prednisone capsules, Beclomethasone dipropionate
- Where
- 3 sites in United States
- Volunteers
- 107 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Cushings Disease, Cushing Disease
Safety and Efficacy of LCI699 in Cushing's Disease Patients
This exploratory study is a proof of concept study to determine whether LCI699 can safely reduce the level of urinary free cortisol in patients with Cushing's disease.
- Trial name
- NCT01331239
- Testing
- LCI699
- Where
- 10 sites in United States, France and 2 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Adult Growth Hormone Deficiency, Hypothalamic-pituitary Disorders
The Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and Adrenocorticotropic Axis
The purpose of this study is to find out if the Glucagon Stimulation Test (GST) is a reliable alternative to the Insulin Tolerance Test (ITT) for diagnosis of Growth Hormone Deficiency (GHD) and adrenal insufficiency.
- Trial name
- GST (NCT01282164)
- Testing
- Glucagon stimulation test and insulin tolerance test
- Where
- 4 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Atopic Dermatitis
Cutivate Lotion HPA Axis Pediatric Study
A multi-center, open-label, Phase IV, unblinded study using Cutivate (fluticasone propionate, 0.05%)lotion and it's possible effects on the HPA axis of infants diagnosed with atopic dermatitis.
- Trial name
- NCT00546000
- Testing
- Fluticasone propionate 0.05% lotion
- Where
- 10 sites in United States
- Volunteers
- 56 people
- Sponsor
- Fougera Pharmaceuticals Inc.
Autonomic Nervous System Imbalance, Hypothalamic Pituitary Adrenal Axis Suppression
Active and Passive Music Therapy Interventions
Purpose: In this preparatory study, the investigators will demonstrate the feasibility of using a structured MT intervention as a treatment for MDD by measuring stress hormone levels and HRV before and after interventions.
- Trial name
- NCT03362944
- Testing
- Active Music Therapy, Passive Music Therapy
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Cortisol Resistance, Negative Feedback
Evaluation of Cortisol Resistance in Young Sedentary and Endurance-Trained Men
This study proposes to examine multiple aspects of the hypothalamic-pituitary-adrenal axis in younger endurance trained and sedentary men, and in older sedentary men.
- Conditions
- Cortisol Resistance, Negative Feedback, ACTH, Mineralcorticoid
- Trial name
- NCT01294319
- Testing
- Mifepristone, Spironolactone, Combined
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Stress Reaction; Acute
Racial Discrimination and Stress Response
The goal of this study is to learn about whether ethnic minority adolescents' racial discrimination experience is related to dysregulated biological responses to subtle racism, and how the relationship may be attenuated or…
- Trial name
- NCT05820659
- Testing
- peer rejection task, conversation about peer rejection, and impossible puzzle task
- Where
- United States
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- Western Kentucky University
Depression, Postpartum, Anxiety Disorders
Inhaled Oxytocin and HPA Axis Reactivity
Mothers who were enrolled in the Mood, Mother and Infant study will be eligible to participate in the 6-year follow-up maternal visit.
- Conditions
- Depression, Postpartum, Anxiety Disorders, Stress, Psychological
- Trial name
- NCT03593473
- Testing
- Intranasal Oxytocin
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- University of North Carolina, Chapel Hill
Perennial Allergic Rhinitis
Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis
To demonstrate the effects of ciclesonide applied as a nasal aerosol and ciclesonide aqueous (AQ) nasal spray on hypothalamic-pituitary-adrenal axis.
- Trial name
- NCT01033825
- Testing
- Ciclesonide HFA Nasal Aerosol 320 mcg, Ciclesonide HFA Nasal Aerosol 160 mcg, Ciclesonide Aqueous Nasal Spray 200 mcg
- Where
- 6 sites in United States
- Volunteers
- 310 people
- Sponsor
- Sumitomo Pharma America, Inc.
Cushings Disease
Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease
The main purpose of this prospective, multicenter, open-label phase II study, was to evaluate the efficacy and safety of pasireotide alone or in combination with cabergoline in patients with Cushing's disease.
- Trial name
- NCT01915303
- Testing
- Pasireotide with or without cabergoline
- Where
- 29 sites in United States, Argentina and 14 more
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals
Cushing's Syndrome
Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
Cushing's syndrome is a relatively rare disorder caused by prolonged exposure to high levels of the glucocorticoid hormone cortisol. Cushing's syndrome may result from elevated endogenous or exogenous sources of cortisol.
- Trial name
- NCT02804750
- Testing
- CORT125134
- Where
- 25 sites in United States, Hungary and 3 more
- Volunteers
- 35 people
- Sponsor
- Corcept Therapeutics
Cushing's Disease, Cushing's Syndrome
Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
This is a compassionate use study. In addition to providing compassionate use access to mifepristone, objectives of the study will be to evaluate the safety and utility of mifepristone in the treatment of the signs and symptoms…
- Trial name
- NCT01371565
- Testing
- Mifepristone
- Where
- 5 sites in United States
- Volunteers
- 4 people
- Sponsor
- Corcept Therapeutics
Cushings Disease
Treatment of Cushing's Disease With R-roscovitine
The investigators hypothesize that R-roscovitine will suppress pituitary corticotroph tumor ACTH production and normalize urinary free cortisol levels in patients with Cushing disease.
- Trial name
- NCT02160730
- Testing
- R-roscovitine
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Shlomo Melmed, MD
Cushing's Syndrome
A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Patients will receive Corlux (mifepristone) daily for up to 24 weeks. Assessments of the signs and symptoms of Cushing's syndrome will be obtained.
- Trial name
- SEISMIC (NCT00569582)
- Testing
- mifepristone
- Where
- 17 sites in United States
- Volunteers
- 50 people
- Sponsor
- Corcept Therapeutics
Cushing Syndrome, Cushing Disease
Open-label Treatment in Cushing's Syndrome
This is a long-term, open-label extension study of levoketoconazole in participants with endogenous Cushing's Syndrome.
- Trial name
- OPTICS (NCT03621280)
- Testing
- Levoketoconazole
- Where
- 30 sites in United States, Bulgaria and 9 more
- Volunteers
- 51 people
- Sponsor
- Cortendo AB
Endogenous Cushing's Syndrome
Treatment for Endogenous Cushing's Syndrome
The primary objectives of this study are to evaluate the clinical responder rate, defined as the proportion of subjects with normal UFC after 6 months of treatment with COR-003 in the Maintenance Phase without dose increase, and…
- Trial name
- SONICS (NCT01838551)
- Testing
- Levoketoconazole
- Where
- 42 sites in United States, Belgium and 13 more
- Volunteers
- 94 people
- Sponsor
- Cortendo AB
Asthma
Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) Axis
The purpose of this study is to assess the effect of six weeks' treatment with two once-daily strengths of Fluticasone Furoate/GW642444 Inhalation Powder on the HPA axis system
- Trial name
- NCT01086410
- Testing
- Fluticasone Furoate/GW642444 Inhalation Powder, Prednisolone Oral Capsule
- Where
- 17 sites in United States, Germany and 1 more
- Volunteers
- 185 people
- Sponsor
- GlaxoSmithKline